Mirati Therapeutics to Present at the 26th Annual Piper Jaffray Healthcare Conference
PR Newswire - Wed Nov 19, 7:00AM CST
Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the company will present a business overview and update at the 26th Annual Piper Jaffray Healthcare Conference on Tuesday, December 2, 2014 at 10:00 a.m. Eastern Time in New York.
MRTX: 15.67 (+0.30)
Mirati beats 3Q profit forecasts
Automated Insights - Mon Nov 10, 7:31AM CST
SAN DIEGO (AP) _ Mirati Therapeutics Inc. (MRTX) on Monday reported a third-quarter loss of $8.6 million.
MRTX: 15.67 (+0.30)
Mirati Therapeutics beats by $0.04
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 7:27AM CST
MRTX: 15.67 (+0.30)
Mirati Therapeutics Reports Third Quarter 2014 Financial Results and Provides Business Update
PR Newswire - Mon Nov 10, 7:00AM CST
Mirati Therapeutics, Inc. ("Mirati"
MRTX: 15.67 (+0.30)
Michael Grey Joins Mirati Therapeutics Board of Directors
PR Newswire - Thu Nov 06, 7:00AM CST
Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that biotechnology industry veteran Michael Grey has joined its board of directors.
MRTX: 15.67 (+0.30)
Mirati Therapeutics to Present at BioCentury's NewsMakers in the Biotech Industry Conference
PR Newswire - Wed Sep 10, 7:00AM CDT
Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the company will present a business overview and update at BioCentury's 21st Annual NewsMakers in the Biotech Industry Conference on Friday, September 26, 2014 at 10:30 a.m. Eastern Time in New York.
MRTX: 15.67 (+0.30)
Mirati Therapeutics Initiates Phase 1 Study of MGCD516 for Non-Small Cell Lung Cancer and Other Advanced Solid Tumors
PR Newswire - Thu Sep 04, 7:00AM CDT
Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the first patient has been dosed in its Phase 1 clinical study of MGCD516 in the treatment of patients with advanced solid tumors, with an initial focus on non-small cell lung cancer (NSCLC). MGCD516 is a Receptor Tyrosine Kinase (RTK) inhibitor with molecular targets that act as critical genetic drivers of cancer progression.
MRTX: 15.67 (+0.30)
Mirati Therapeutics Receives Orphan Designation from U.S. Food & Drug Administration for Mocetinostat in Diffuse Large B-Cell Lymphoma
PR Newswire - Mon Aug 11, 7:00AM CDT
Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the U.S. FDA has granted Orphan Drug Designation to mocetinostat, a spectrum selective HDAC inhibitor, for diffuse large B-cell lymphoma (DLBCL). In June, mocetinostat was granted Orphan Drug Designation as a treatment for myelodysplastic syndrome (MDS). Orphan drug designation is also being sought for bladder cancer patients with specific genetic alterations.
MRTX: 15.67 (+0.30)
Mirati Therapeutics Reports Second Quarter 2014 Financial Results and Provides Business Update
PR Newswire - Fri Aug 08, 7:00AM CDT
Mirati Therapeutics, Inc. ("Mirati"
MRTX: 15.67 (+0.30)
Mirati Therapeutics Added to Russell 2000 Index
PR Newswire - Mon Jun 30, 3:01PM CDT
Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the company has been added to the Russell 2000® Index following the annual reconstitution of its U.S. and global equity indexes on June 27, 2014.
MRTX: 15.67 (+0.30)
Mirati Therapeutics Receives Orphan Drug Designation from U.S. Food & Drug Administration for Mocetinostat in Myelodysplastic Syndrome
PR Newswire - Tue Jun 17, 7:00AM CDT
Mirati Therapeutics, Inc. (NASDAQ: MRTX) announced that mocetinostat, the company's spectrum selective HDAC inhibitor, has been granted Orphan Drug Designation by the U.S. Food & Drug Administration as a treatment for myelodysplastic syndrome (MDS). Mocetinostat is being developed in Phase 2 clinical studies in combination with Vidaza as a treatment for intermediate and high-risk MDS, as well as a single agent treatment in patients with diffuse large B-cell lymphoma (DLBCL) and bladder cancer targeting specific genetic mutations in histone acetylation that increase the likelihood of response in tumor cells.
MRTX: 15.67 (+0.30)
Mirati Therapeutics to Present at the 9th Annual JMP Securities Healthcare Conference
PR Newswire - Thu Jun 12, 7:00AM CDT
Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the company will present at the 9th Annual JMP Securities Healthcare Conference on Wednesday, June 25, 2014 at 9:00 a.m. Eastern Time in New York.
MRTX: 15.67 (+0.30)